ElevateBio and Affini-T collaborate to develop T cell therapies
Pharmaceutical Technology
NOVEMBER 16, 2022
Affini-T’s platform can choose and engineer the correct immune cells to create a lasting and coordinated immune response in the immunosuppressive tumour microenvironment. To act on oncogenic driver mutations, Affini-T is using engineered T-cell therapies with synthetic biology and gene editing enhancements.
Let's personalize your content